MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Intra-Cellular Therapies Company Profile (NASDAQ:ITCI)

Consensus Ratings for Intra-Cellular Therapies (NASDAQ:ITCI) (?)
Ratings Breakdown: 7 Buy Rating(s), 1 Strong Buy Rating(s)
Consensus Rating:Buy (Score: 3.13)
Consensus Price Target: $74.38 (114.58% upside)

Analysts' Ratings History for Intra-Cellular Therapies (NASDAQ:ITCI)
Show:
DateFirmActionRatingPrice TargetActions
6/22/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/22/2016Piper JaffrayReiterated RatingOverweight$57.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/28/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/29/2016SunTrustReiterated RatingTop Pick$60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$62.00 -> $55.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/6/2015RBC CapitalBoost Price TargetOutperform$62.00 -> $74.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/29/2015GuggenheimBoost Price TargetBuy$95.00 -> $104.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/17/2015Ladenburg ThalmannReiterated RatingBuy$54.00 -> $75.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/27/2014 forward)
Earnings History for Intra-Cellular Therapies (NASDAQ:ITCI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
4/28/2016Q116($0.78)($0.64)$0.02 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q415($0.87)($0.67)$0.05 million$30.66 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.66)($0.91)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.72)($0.61)$40.00 million$57.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q1($0.68)($0.72)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015($0.49)($0.52)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2014Q314($0.28)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014Q214($0.23)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014($0.23)($0.17)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/26/2014($0.41)($0.36)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Intra-Cellular Therapies (NASDAQ:ITCI)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.74)($0.63)($0.69)
Q2 20162($0.79)($0.65)($0.72)
Q3 20163($0.82)($0.66)($0.71)
Q4 20161($0.93)($0.93)($0.93)
(Data provided by Zacks Investment Research)
Dividend History for Intra-Cellular Therapies (NASDAQ:ITCI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Intra-Cellular Therapies (NASDAQ:ITCI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
2/29/2016Christopher D AlafiDirectorBuy100,000$29.70$2,970,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2015Lawrence J. HinelineCFOSell45,000$51.45$2,315,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2015Sharon MatesCEOSell51,500$53.87$2,774,305.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2015Joel S MarcusDirectorSell92,700$54.47$5,049,369.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2015Lawrence J HinelineCFOSell5,000$55.00$275,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Lawrence P WennogleVPSell25,000$26.84$671,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2015Christopher D AlafiDirectorBuy625,000$24.00$15,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2014Lawrence J HinelineCFOSell22,500$16.71$375,975.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Moshe AlafiMajor ShareholderBuy1,422$14.75$20,974.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/28/2014Christopher D AlafiDirectorBuy35,000$14.75$516,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2014Alafi Capital Co LlcMajor ShareholderBuy1,034$14.25$14,734.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2014Alafi Capital Co LlcMajor ShareholderBuy3,664$14.26$52,248.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2014Alafi Capital Co LlcMajor ShareholderBuy12,200$15.34$187,148.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/6/2014Michael HalsteadSVPBuy20,000$15.38$307,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2014Lawrence P WennogleVPSell3,604$15.00$54,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/13/2014Lawrence P WennogleVPSell1,600$15.00$24,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/8/2014Lawrence P WennogleVPSell4,745$15.00$71,175.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/6/2014Lawrence P WennogleVPSell16,499$15.00$247,485.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2014Lawrence P WennogleVPSell5,000$15.00$75,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2014Lawrence J HinelineCFOSell300$15.00$4,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2014Lawrence P WennogleVPSell6,000$15.00$90,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Intra-Cellular Therapies (NASDAQ:ITCI)
DateHeadline
06/27/16 04:41 PMStock Volatility in Review: Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Engelwood Daily
06/27/16 03:14 PMIntra-Cellular Therapies, Inc. – Value Analysis (NASDAQ:ITCI) : June 27, 2016 -
06/25/16 04:24 PMIntra-Cellular Therapies Inc. (ITCI) Jumps 5.1% on June 23 - Equities.com
06/24/16 07:37 AMIntra-Cellular Therapies, Inc. breached its 50 day moving average in a Bullish Manner : ITCI-US : June 24, 2016 -
06/22/16 04:49 PMIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock Momentum Hits Weakness - CML News
06/22/16 04:49 PMIntra-Cellular Therapies Inc. (ITCI) Drops 5.33% on June 21 - Equities.com
06/18/16 09:04 AMIntra-Cellular Therapies (ITCI): Today's Weak On High Volume Stock - TheStreet.com
06/15/16 03:17 PMINTRA-CELLULAR THERAPIES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/15/16 09:20 AMIntra-Cellular Therapies to Present at the JMP Securities Life Sciences Conference - EIN News (press release)
06/15/16 08:09 AMIntra-Cellular Therapies to Present at the JMP Securities Life Sciences Conference - [at noodls] - NEW YORK, June 15, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ('CNS') disorders, ...
06/08/16 05:00 PMINTRA-CELLULAR THERAPIES INC. (NASDAQ:ITCI) Financial Condition Compared to S&P 500 - CML News
06/04/16 07:28 AMPiper Jaffray Indicated Intra-Cellular Therapies (NASDAQ:ITCI) As 'Overweight' - FTSE News
06/04/16 07:28 AMBiotech Movers Update: Intra-Cellular Therapies Inc. (NASDAQ:ITCI) , Accuray Incorporated (NASDAQ:ARAY) - Is stories
06/02/16 04:58 PMIntra-Cellular Therapies (NASDAQ:ITCI) indicated as 'Overweight' At Piper Jaffray - Share Trading News - Share Trading NewsIntra-Cellular Therapies (NASDAQ:ITCI) indicated as 'Overweight' At Piper JaffrayShare Trading NewsIntra-Cellular Therapies (NASDAQ:ITCI) indicated as 'Overweight' At Piper Jaffray. By Brenton Akerman / in US Broker Ratings / on Wednesday, 01 Jun 2016 11:21 PM / 0 Comments. According to a research report issued by Piper Jaffray on Wednesday, ...and more »
06/02/16 06:36 AMCoverage initiated on Intra-Cellular Therapies by Piper Jaffray -
05/31/16 09:02 AMStock Rating Review for Intra-Cellular Therapies Inc. (NASDAQ:ITCI) - HNN - Stock Rating Review for Intra-Cellular Therapies Inc. (NASDAQ:ITCI)HNNCovering equity analysts presently have a consensus stock rating of 1 on shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI). Covering analysts will often provide Sell, Hold, or Buy recommendations based on their advanced research. This consensus ...
05/31/16 07:22 AMIntra-Cellular Therapies to Present at the Jefferies 2016 Healthcare Conference - [at noodls] - NEW YORK, May 31, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ('CNS') disorders, ...
05/27/16 07:33 PMHold Calls Count For Intra-Cellular Therapies Inc. (NASDAQ:ITCI) At 0 - RealistInvestor.com - Hold Calls Count For Intra-Cellular Therapies Inc. (NASDAQ:ITCI) At 0RealistInvestor.comBuy calls count on Intra-Cellular Therapies Inc. (NASDAQ:ITCI)'s stock stands at 0 while Sell recommendations is 0. Hold recommendation is 0. Intra-Cellular Therapies Inc. (NASDAQ:ITCI) has a total of 5 Strong Buy recommendations and 0 Strong Sell ...Earnings Review and Stock Rundown for Intra-Cellular Therapies Inc. (NASDAQ:ITCI)Wall Street Hints and Newsall 540 news articles »
05/26/16 07:27 AMIntra-Cellular Therapies to Present at the American Society of Clinical Psychopharmacology 2016 Annual Meeting - [at noodls] - NEW YORK, May 26, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, ...
05/25/16 06:56 PMEarnings Review and Stock Rundown for Intra-Cellular Therapies Inc. (NASDAQ:ITCI) - Wall Street Hints and News - Earnings Review and Stock Rundown for Intra-Cellular Therapies Inc. (NASDAQ:ITCI)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Intra-Cellular Therapies Inc. (NASDAQ ...and more »
05/25/16 12:31 AMIntra Cellular Therapies Incorporated (NASDAQ:ITCI) Short Interest Decreased By 1.43% - Wall Street Hints and News - Intra Cellular Therapies Incorporated (NASDAQ:ITCI) Short Interest Decreased By 1.43%Wall Street Hints and NewsThe short interest to Intra Cellular Therapies Incorporated's float is 13.5%. The stock increased 0.46% or $0.17 during the last trading session, hitting $36.91. About 359,318 shares traded hands. Intra-Cellular Therapies Inc (NASDAQ:ITCI) has declined ...and more »
05/25/16 12:31 AMIntra-Cellular Therapies Inc (ITCI) is Trading Higher on Unusual Volume for May 23 - Equities.com - Intra-Cellular Therapies Inc (ITCI) is Trading Higher on Unusual Volume for May 23Equities.comIntra-Cellular Therapies Inc (ITCI) experienced unusually high volume on May. 23, as the stock gained 4.29% to a closing price of $36.74. The stock saw 572,925 shares trade hands over the course of the day on 5,279 trades. Given that the stock's ...
05/24/16 07:13 PMTarget Check and Stock Performance Recap Intra-Cellular Therapies Inc. (NASDAQ:ITCI) - Wall Street Hints and News - Target Check and Stock Performance Recap Intra-Cellular Therapies Inc. (NASDAQ:ITCI)Wall Street Hints and NewsTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Intra-Cellular Therapies Inc.and more »
05/24/16 12:13 AMFour Biotech Picks With 2016 Catalysts - ($41 price target), Intra-Cellular Therapies ( ITCI ITCI 3.775191598069827% Intra-Cellular Therapies Inc. U.S.: Nasdaq USD 36.56 1.33 3.775191598069827% /Date(1464036541322-0500)/ Volume (Delayed 15m) : 453816 P/E Ratio N/A Market Cap 1523098630.41702 ...
05/23/16 07:02 PMStock Rating Review for Intra-Cellular Therapies Inc. (NASDAQ:ITCI) - Wall Street Hints and News - Stock Rating Review for Intra-Cellular Therapies Inc. (NASDAQ:ITCI)Wall Street Hints and NewsCovering equity analysts presently have a consensus stock rating of 1 on shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI). Covering analysts will often provide Sell, Hold, or Buy recommendations based on their advanced research. This consensus ...and more »
05/23/16 07:02 PMIntra-Cellular Therapies Inc. (NASDAQ:ITCI) Closes At $35.23 - RealistInvestor.com - Intra-Cellular Therapies Inc. (NASDAQ:ITCI) Closes At $35.23RealistInvestor.comThe technical analysis of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) stock highlights the stock is $1.67 points away +4.89% from its 50-day MA of $34.06. It is $-3.83 or -9.67% away $39.56, the 200-day Moving Average (MA) of stock. Yesterday, the ...
05/20/16 12:17 AMIntra Cellular Therapies Incorporated (NASDAQ:ITCI) Shorts Decreased by 1.43% After Short Covering - Wall Street Hints and News - Intra Cellular Therapies Incorporated (NASDAQ:ITCI) Shorts Decreased by 1.43% After Short CoveringWall Street Hints and NewsThe short interest to Intra Cellular Therapies Incorporated's float is 13.5%. The stock decreased 1.07% or $0.37 on May 19, hitting $34.22. About 338,782 shares traded hands. Intra-Cellular Therapies Inc (NASDAQ:ITCI) has declined 17.32% since October ...
05/19/16 07:00 PMShare Recap and Earnings Focus on Intra-Cellular Therapies Inc. (NASDAQ:ITCI) - Wall Street Hints and News - Share Recap and Earnings Focus on Intra-Cellular Therapies Inc. (NASDAQ:ITCI)Wall Street Hints and NewsAnalysts and investors are usually very focused on company earnings numbers when they are released. Company earnings are a good way to evaluate the profitability of the company. Presently, covering analysts are anticipating Intra-Cellular Therapies Inc.Intra-Cellular Therapies Gains 4% – Presents Additional Positive Data on Schizophrenia Studies (NASDAQ:ITCI)Sonoran Weekly ReviewIntra-Cellular Therapies presents at the Annual Meetings of the Society of Biological Psychiatry and the American ...GlobeNewswire (press release)How Many ITI Inc (NASDAQ:ITCI)'s Analysts Are Bearish?Franklin Independentall 5 news articles »
05/18/16 06:42 AMIntra-Cellular Therapies presents at the Annual Meetings of the Society of Biological Psychiatry and the American Psychiatric Association - [at noodls] - NEW YORK, May 18, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, ...
05/17/16 11:54 PMShare Performance and Target Price Review for Intra-Cellular Therapies Inc. (NASDAQ:ITCI) - Wall Street Hints and News - Share Performance and Target Price Review for Intra-Cellular Therapies Inc. (NASDAQ:ITCI)Wall Street Hints and NewsLooking at stock activity from multiple angles may be of benefit when examining share performance. Investors have the ability to focus in on short or long term share performance. During the most recent trading session, Intra-Cellular Therapies Inc.and more »
05/17/16 11:54 PMIntra-Cellular Therapies Inc (ITCI) Jumps 7.03% on May 16 - Equities.com - Intra-Cellular Therapies Inc (ITCI) Jumps 7.03% on May 16Equities.comIntra-Cellular Therapies Inc (ITCI) was among the biggest gainers on the Russell 2000 for Monday May 16 as the stock popped 7.03% to $34.71, representing a gain of $2.28 per share. Some 285,226 shares traded hands on 2,908 trades, compared with an ...Hot Alert: Threshold Pharmaceuticals Inc. (NASDAQ:THLD), Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), Verizon ...KC RegisterHow Many ITI Inc (NASDAQ:ITCI)'s Analysts Are Bearish?Franklin Independentall 3 news articles »
05/16/16 12:26 PMConsensus Rating Review for Intra-Cellular Therapies Inc. (NASDAQ:ITCI) - Wall Street Hints and News - Consensus Rating Review for Intra-Cellular Therapies Inc. (NASDAQ:ITCI)Wall Street Hints and NewsEquity research analysts currently have a consensus rating of 1 on shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy ...and more »
05/16/16 12:26 PMIntra-Cellular Therapies Inc. (NASDAQ:ITCI) Hovering Around ${[p}} - RealistInvestor.com - Intra-Cellular Therapies Inc. (NASDAQ:ITCI) Hovering Around ${[p}}RealistInvestor.comOn performing technical analysis of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) stock, it is noted that the stock is $0.47 points away +1.40% from its fifty-day MA of $33.25. It is $-6.43 or -16.01% away $40.15, the 200-day MA (Moving Average) of stock ...Intra-Cellular Therapies Inc. (NASDAQ:ITCI) Basic Consolidated EPS At $-2.9054Equities FocusIntra Cellular Therapies Incorporated (NASDAQ:ITCI) Sellers Covered 1.43% of Their ShortsFranklin Independentall 3 news articles »
05/10/16 07:35 PMPerformance Recap and Target Perspective on Intra-Cellular Therapies Inc. (NASDAQ:ITCI) - B.O.D.Y Confidential - Performance Recap and Target Perspective on Intra-Cellular Therapies Inc. (NASDAQ:ITCI)B.O.D.Y ConfidentialSome investors may pay more attention to short short-term share performance, while others may be more interested in stock action over a longer period of time. In the latest trading session, shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) moved +6 ...and more »
05/10/16 07:18 AMIntra-Cellular Therapies to Present at the American Psychiatric Association 169th Annual Meeting and the Society of Biological Psychiatry 71st Annual Meeting - [at noodls] - NEW YORK, May 10, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, ...
05/10/16 12:20 AMIntra-Cellular Therapies Inc (ITCI) Jumps 6.94% on May 09 - Equities.com - Intra-Cellular Therapies Inc (ITCI) Jumps 6.94% on May 09Equities.comIntra-Cellular Therapies Inc (ITCI) was among the biggest gainers on the Russell 2000 for Monday May 09 as the stock popped 6.94% to $33.14, representing a gain of $2.15 per share. Some 346,583 shares traded hands on 3,579 trades, compared with an ...
05/09/16 07:12 PMCheck on Analyst Ratings Intra-Cellular Therapies Inc. (NASDAQ:ITCI) - B.O.D.Y Confidential - Check on Analyst Ratings Intra-Cellular Therapies Inc. (NASDAQ:ITCI)B.O.D.Y ConfidentialCovering Wall Street analysts have an average rating of 1 on shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI). This Zacks Research number is compiled from analysts that they have taken into consideration. This consensus rating falls on a 1 to 5 scale.and more »
05/09/16 07:43 AMIntra-Cellular Therapies, Inc. breached its 50 day moving average in a Bearish Manner : ITCI-US : May 9, 2016 -
05/07/16 06:33 PMWhy Intra-Cellular Therapies Inc Stock Jump 21.4% in April - Motley Fool - Motley FoolWhy Intra-Cellular Therapies Inc Stock Jump 21.4% in AprilMotley FoolWhat: Shares of Intra-Cellular Therapies (NASDAQ:ITCI), a clinical-stage biopharma focused on creating products that treat diseases of the central nervous system, soared more than 21% higher during the month, according to data from S&P Global Market ...Intra-Cellular Therapies Inc (ITCI) Drops 8.24% on May 04Equities.comIntra Cellular Therapies Incorporated (NASDAQ:ITCI) Shorted Shares Increased 0.36% After Market SellingThe PostIntra-Cellular Therapies Inc. (NASDAQ:ITCI): Quick Look at Company EarningsNews TribuneWeb Breaking Newsall 6 news articles »
05/07/16 10:21 AMWhy Intra-Cellular Therapies Inc Stock Jump 21.4% in April - Shares bounced back from a rough start to the year after management made the rounds at a handful of investor conferences.
05/06/16 01:38 AMEarnings Outlook on Intra-Cellular Therapies Inc. (NASDAQ:ITCI) - B.O.D.Y Confidential - Earnings Outlook on Intra-Cellular Therapies Inc. (NASDAQ:ITCI)B.O.D.Y ConfidentialAnalysts and investors will be anticipating Intra-Cellular Therapies Inc. (NASDAQ:ITCI)'s next earnings release which is expected to be posted on or around 2016-08-03. Sell-side research firms on Wall Street are expecting that the company will post EPS ...Were Analysts Bullish Intra-Cellular Therapies Inc (NASDAQ:ITCI) This Week?The PostIntra-Cellular Therapies Inc (ITCI) Forecasted to Earn FY2016 Earnings of ($3.20) Per ShareWeb Breaking Newsall 5 news articles »
05/05/16 08:20 PMIntra-Cellular Therapies Inc (ITCI) Drops 8.24% on May 04 - Equities.com - Intra-Cellular Therapies Inc (ITCI) Drops 8.24% on May 04Equities.comIntra-Cellular Therapies Inc (ITCI) was one of the Russell 2000's biggest losers for Wednesday May 04 as the stock slid 8.24% to $32.18, a loss of $-2.89 per share. Starting at an opening price of $34.64 a share, the stock traded between $32.07 and $34 ...Intra-Cellular Therapies Inc. (NASDAQ:ITCI): Quick Look at Company EarningsNews Tribuneall 2 news articles »
05/05/16 12:04 PMINTRA-CELLULAR THERAPIES, INC. Financials -
05/04/16 07:20 AMIntra-Cellular Therapies to Present at the Bank of America Merrill Lynch 2016 Health Care Conference - [at noodls] - NEW YORK, May 04, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ('CNS') disorders, ...
05/02/16 08:56 PMAverage Analyst Rating for Intra-Cellular Therapies Inc. (NASDAQ:ITCI) - B.O.D.Y Confidential - Average Analyst Rating for Intra-Cellular Therapies Inc. (NASDAQ:ITCI)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1 on Intra-Cellular Therapies Inc. (NASDAQ:ITCI) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks Research.and more »
04/29/16 05:54 PMEdited Transcript of ITCI earnings conference call or presentation 28-Apr-16 12:30pm GMT -
04/28/16 08:32 AMIntra-Cellular reports 1Q loss -
04/28/16 06:22 AMIntra-Cellular Therapies Reports First Quarter 2016 Financial Results and Provides Corporate Update - [at noodls] - NEW YORK, April 28, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, ...
04/28/16 06:19 AMINTRA-CELLULAR THERAPIES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Finan -
04/28/16 06:06 AM7:06 am Intra-Cellular Therapies beats by $0.17 -
About Intra-Cellular Therapies

Intra-Cellular Therapies logoIntra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company's pipeline includes approximately two product candidates in clinical development and two product candidates in advanced pre-clinical testing. Its platform includes ITI-007 platform and phosphodiesterase (PDE) Inhibitor Platform. It is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, behavioral disturbances associated with dementia, autism and other CNS diseases. Its ITI-007 platform also includes long acting injectable (LAI) program, and IC200131 program for mood and other disorders. Its PDE Inhibitor Platform includes PDE1 program and PDE2 and PDE9 programs.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ITCI
  • CUSIP:
Key Metrics:
  • Previous Close: $34.66
  • 50 Day Moving Average: $36.95
  • 200 Day Moving Average: $37.01
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $1.50B
  • Current Quarter EPS Consensus Estimate: $-3.21 EPS
Additional Links:
Intra-Cellular Therapies (NASDAQ:ITCI) Chart for Monday, June, 27, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha